Close

Anti-CD56 scFv h(41BB-CD3ζ) CART, pCDCAR1 (CAR-T-2-M312-BZ)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-CD56 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD56. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD56 antibody linked to CD137 (4-1BB) and CD3-zeta signaling domains. And the vector product was designed for the treatment of relapsed refractory myeloma.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • CD56
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • Relapsed refractory myeloma
  • Generation
  • Second
  • Vector Name
  • pCDCAR1
  • Vector Length
  • 8kb
  • Vector Type
  • Lentiviral
  • Receptor Construction
  • scFv-41BB-CD3ζ
  • Discription of Signaling Cassetes
  • 41BB
    CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigen-nonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • N901
  • Host
  • Mouse
  • Target Species
  • Human
  • Gene Name
  • Neural cell adhesion molecule
  • Synonyms
  • NCAM1; CD56; MSK39; NCAM; neural cell adhesion molecule 1

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
Complete CAR data Cyt

Fig.1 CD56R-specific CAR T cells kill CD56-expressing targets in vitro.

CAR Construction : N901-CD28-CD3ζ Latest CAR Construction

Fig.1 CD56R-specific CAR T cells kill CD56-expressing targets in vitro.

Chromium release assays of CD56R-CAR+ T cells co-cultured 20:1 with the following targets: Neuroblastoma (CHLA-255, IMR-32, SKN-BE, and SK-N-SH) and SCLC (HTB-119) cell lines; NK-cell leukemia (KHYG1) and glioma/astrocytoma (U87) cell lines.

Crossland, D. L., Denning, W. L., Ang, S., Olivares, S., Mi, T., Switzer, K., ... & Heymach, J. V. (2018). Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models. Oncogene, 37(27), 3686-3697.

Complete CAR data FCM

Fig.2 Anti- or pro-tumor cytokine expression.

CAR Construction : N901-CD28-CD3ζ Latest CAR Construction

Fig.2 Anti- or pro-tumor cytokine expression.

Expression anti- or pro-tumor cytokine of CD4+ and CD8+ CD56R-CAR+ T cells was detected by intracellular flow cytometry after culturing CD3+ CD56R-CAR+ T cells in the diffrent conditions.

Crossland, D. L., Denning, W. L., Ang, S., Olivares, S., Mi, T., Switzer, K., ... & Heymach, J. V. (2018). Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models. Oncogene, 37(27), 3686-3697.

Complete CAR data BI

Fig.3 The ability of CD56R-CAR+T to control tumor growth in vivo.

CAR Construction : Latest CAR Construction

Fig.3 The ability of CD56R-CAR+T to control tumor growth in vivo.

CD56R-CAR+ T cells inhibit the growth of human CD56+ tumors in the high/low tumor-burden CD56+ neuroblastoma mouse model..

Crossland, D. L., Denning, W. L., Ang, S., Olivares, S., Mi, T., Switzer, K., ... & Heymach, J. V. (2018). Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models. Oncogene, 37(27), 3686-3697.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CD56 scFv h(41BB-CD3ζ) CART, pCDCAR1 (CAR-T-2-M312-BZ). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.